Cure8 research brief
The study shows that fecal (luminal) and mucosal microbiome and metabolite profiles capture different aspects of pediatric IBD—activity versus phenotype—so combined sampling may give a fuller picture for research and future biomarker development.
Pediatric gastroenterologists, microbiome researchers, clinicians interested in biomarkers or multi-omic profiling, and parents/caregivers of children with IBD.
The researchers combined bacterial and fungal sequencing, fecal metabolomics, and measurements of host- and microbe-derived biomarkers (for example, IgA, lysozyme, bile acids, and urinary indican) from luminal and mucosal compartments.
They report that luminal communities showed coordinated taxonomic and metabolic changes tied to inflammatory activity, including shifts in microbial metabolites and host biomarkers consistent with altered fermentation and proteolytic metabolism.
Mucosal differences were more linked to disease phenotype, particularly in the fungal community, while mucosal bacterial changes were less pronounced. Overall, the paper supports using compartment-specific, integrated multi-omic profiling (luminal + mucosal) to better understand and potentially stratify pediatric IBD.
Findings are presented in the article abstract and reflect associations across integrated omics datasets; they do not constitute validated clinical diagnostics or therapeutic recommendations.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.
This study suggests machine learning of stool microbiome data could eventually help distinguish IBD (especially Crohn’s) from healthy people and some other bowel or systemic conditions.
Researchers report links between copper-driven cell death pathways and IBD biology; identifying cuproptosis-related biomarkers or drugs could open new diagnostic or therapeutic avenues for people with Crohn's disease or...
